David Dornan

David Dornan

UNVERIFIED PROFILE

Are you David Dornan?   Register this Author

Register author
David Dornan

David Dornan

Publications by authors named "David Dornan"

Are you David Dornan?   Register this Author

29Publications

896Reads

43Profile Views

Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Cancer Discov 2018 02 3;8(2):196-215. Epub 2017 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809290PMC
February 2018

miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.

PLoS One 2013 11;8(6):e66502. Epub 2013 Jun 11.

Department of Molecular Diagnostics and Cancer Cell Biology, Genentech, Inc., South San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066502PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679042PMC
January 2014

To respond or not to respond to CD40 agonism: That is the prediction.

Oncoimmunology 2012 Jan;1(1):83-85

Molecular Diagnostics and Cancer Cell Biology; Genentech, Inc.; South San Francisco, CA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.1.1.17827DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376969PMC
January 2012

Dissecting cancer heterogeneity.

Nat Biotechnol 2011 Dec 8;29(12):1095-6. Epub 2011 Dec 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt.2063DOI Listing
December 2011

Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data.

BMC Cancer 2010 Oct 27;10:586. Epub 2010 Oct 27.

Biometric Research Branch - Department of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health. Rockville, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-10-586DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984428PMC
October 2010

Cancer: miRNA addiction - depending on life's little things.

Curr Biol 2010 Sep;20(18):R812-3

Genentech, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cub.2010.08.040DOI Listing
September 2010

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.

Nature 2010 Jan 20;463(7277):103-7. Epub 2009 Dec 20.

Department of Physiological Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature08646DOI Listing
January 2010

ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage.

Science 2006 Aug;313(5790):1122-6

Department of Physiological Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.1127335DOI Listing
August 2006

Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53.

Mol Cell Biol 2004 Nov;24(22):10083-98

CRUK Interferon and Cell Signalling Group, Cell Signalling Unit, Cancer Research Centre, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.24.22.10083-10098.2004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC525491PMC
November 2004

COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas.

Cancer Res 2004 Oct;64(20):7226-30

Department of Molecular Oncology, Genentech, Inc., South San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-2601DOI Listing
October 2004

The ubiquitin ligase COP1 is a critical negative regulator of p53.

Nature 2004 May 21;429(6987):86-92. Epub 2004 Apr 21.

Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature02514DOI Listing
May 2004

Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase.

Science 2004 Feb 22;303(5662):1371-4. Epub 2004 Jan 22.

Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.1093549DOI Listing
February 2004

The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.

Mol Cell Biol 2003 Dec;23(23):8846-61

Cancer Research UK Laboratories, P53 Signal Transduction Group, Department of Molecular and Cellular Pathology, University of Dundee, Dundee DD1 9SY, United Kingdom.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC262654PMC
http://dx.doi.org/10.1128/mcb.23.23.8846-8861.2003DOI Listing
December 2003

DNA-dependent acetylation of p53 by the transcription coactivator p300.

J Biol Chem 2003 Apr 23;278(15):13431-41. Epub 2002 Dec 23.

Cancer Research UK Laboratories, Department of Molecular & Cellular Pathology, University of Dundee, Dundee DD1 9SY, Scotland, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M211460200DOI Listing
April 2003

Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway.

Oncogene 2002 Nov;21(51):7776-85

Cancer Research UK Laboratories, University of Dundee Medical School, Dundee DD1 9SY, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1205981
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1205981DOI Listing
November 2002

The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.

J Biol Chem 2002 Aug 29;277(32):28446-58. Epub 2002 Mar 29.

Department of Molecular and Cellular Pathology, The Cancer Research UK Laboratories, The University of Dundee, Dundee DD1 9SY, Scotland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M202296200DOI Listing
August 2002